Form 4: Avadel Pharmaceuticals Director Peter J. Thornton Acquires 10,000 Shares

Director Peter J. Thornton acquired 10,000 ordinary shares of Avadel Pharmaceuticals at a price of $8.045 per share on January 13, 2025.

Summary

• Peter J. Thornton, a director of Avadel Pharmaceuticals, purchased 10,000 ordinary shares of the company.
• The transaction occurred on January 13, 2025.
• The purchase price was $8.045 per share.
• Following the transaction, Mr. Thornton directly owns 104,055 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as a director purchasing shares can be seen as a sign of confidence, but it's a routine transaction.

Positives

• A director's purchase of shares can be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a routine disclosure of a transaction by a company insider, which is common in the pharmaceutical industry and is required by the SEC.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and this transaction is within the normal range of such activities.
• Similar transactions are regularly reported by directors and officers of other pharmaceutical companies such as Jazz Pharmaceuticals, and Alkermes.

Stakeholder Impact

• The purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Avadel Pharmaceuticals, share purchase, director, insider trading, equity, ordinary shares, Peter J. Thornton